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Transcription of the rat CYP24 gene is induced by
1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) through two vi-
tamin D response elements (VDREs). A functional Ras-
dependent Ets-binding site (EBS) was located down-
stream from the proximal VDRE and was critical to
1,25(OH)2D3-mediated induction. Cotransfection of Ets-1
and Ets-2 stimulated induction, which was lost when the
EBS was mutated. Multiple nuclear-protein complexes
from COS-1 cells bound to the EBS in which three com-
plexes were immunologically related to Ets-1. Tran-
scriptional synergy was observed between the proximal
VDRE and adjacent EBS as was the attendant formation
of a ternary complex between vitamin D receptor- reti-
noid X receptor (VDRzRXR) and Ets-1. In the absence of
1,25-(OH)2D3 or in the presence of an inactive proximal
VDRE, the EBS failed to respond to exogenous Ets-1.
However, Ets-1 increased basal expression when co-
transfected with a mutant VDR. The inductive action of
1,25-(OH)2D3 was substantially increased by Ras, which
was ablated by mutagenesis of the EBS or by expression
of a mutated Ets-1 protein (T38A). EBS contribution to
hormone induction was prevented by manumycin A, an
inhibitor of Ras farnesylation. A fundamental role was
established for transcriptional cooperation between
Ras-activated Ets proteins and the VDRzRXR complex in
mediating 1,25-(OH)2D3 action on the CYP24 promoter.
The hormone 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3
1 or
calcitriol) is a pleiotropic secosteroid that directs many bio-
chemical and cellular functions associated with calcium home-
ostasis, cellular proliferation and differentiation, and the im-
mune response (1–4). The transcriptional regulation of target
genes by 1,25-(OH)2D3 is mediated by the vitamin D receptor
(VDR), a member of the ligand-dependent nuclear receptor
superfamily (5–9). The liganded VDR in association with its
partner retinoid X receptor (RXR) (a member of the nuclear
receptor superfamily) binds to specific control elements re-
ferred to as vitamin D response elements (VDREs) that are
located in the promoter of target genes (8–9). Current evidence
suggests the VDRzRXR heterodimeric complex binds to the
VDRE in the unliganded state (3, 10) and is subsequently
activated following ligand binding. Transactivation of the tar-
get gene is achieved through an intermediary coactivator com-
plex that functions to link the VDRzRXR receptor complex to
the RNA polymerase II holoenzyme (10–12).
The level of expression of 1,25-(OH)2D3-responsive genes in
tissues is dependent on the presence of VDR and the concen-
tration of intracellular 1,25-(OH)2D3. Steady-state levels of
1,25-(OH)2D3 in cells and the circulation are determined by a
balance between 1,25-(OH)2D3 bioactivation and degradation
(1). The rate-limiting step in the bioactivation pathway is cat-
alyzed by 25-hydroxyvitamin D3 1-hydroxylase (13, 14), and
the kidney is the major site of synthesis of biologically active
1,25-(OH)2D3. Metabolic inactivation of 1,25-(OH)2D3 and con-
version to water-soluble products are catalyzed by the C24
oxidation pathway (15). The initial step in this pathway in-
volves the mitochondrial cytochrome P450C24 enzyme (i.e. 25-
hydroxyvitamin D3 24-hydroxylase, CYP24) (16). In the normal
situation, CYP24 is expressed mainly in the kidney but can be
substantially induced by 1,25-(OH)2D3 in this and many other
tissues. The up-regulation of CYP24 in response to 1,25-
(OH)2D3 constitutes an important negative feedback mecha-
nism, whereby the hormone acts to regulate its ambient and
cellular concentration. Hence, expression of CYP24 in kidney
and other tissues serves a protective function in guarding
against excessive levels of 1,25-(OH)2D3 that can be deleterious
due to the attendant hypercalcemia. In addition, specific bio-
logical actions in bone have been reported for 24,25-dihy-
droxyvitamin D3 (24,25-(OH)2D3) (17), a metabolite whose cel-
lular concentration is directed by regulation of CYP24 gene
expression. It is clear, therefore, that regulation of CYP24 gene
expression is important in the metabolism and function of
metabolites from the vitamin D pathway.
Studies into the molecular mechanism by which 1,25-
(OH)2D3 induces the CYP24 gene are in progress (18–21). In
the rat promoter, there are two functional VDREs located at
2136/2150 and 2244/2258 on the antisense strand (18). To
date, this dual arrangement of VDREs is unique among the
1,25-(OH)2D3-responsive genes. The two VDREs conform to the
classic sequence, each consisting of two direct repeats sepa-
rated by a 3-bp spacer. Gel mobility shift analysis using anti-
bodies has established that both VDREs bind heterodimeric
complexes of VDRzRXR (18). Transcriptional synergy between
the two VDREs has been demonstrated and is particularly
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evident at high levels of 1,25-(OH)2D3 (18). Indeed, the CYP24
promoter appears to be the most responsive promoter to 1,25-
(OH)2D3 so far identified with levels of induction of 20–70-fold
being observed in transient assays (21). In our previous studies
on the rat CYP24 promoter, we unexpectedly observed that the
proximal VDRE had greater transactivation ability than the
distal VDRE, yet its affinity for the VDRzRXR complex in gel
mobility shift assays was markedly lower (18). This finding
raised the possibility of transcriptional cooperation between
the VDRzRXR complex and nearby transcription factors (22).
To investigate this possibility, we used computer analysis to
identify both an Ets-binding site and a possible AP-1 site jux-
taposed and downstream to the proximal VDRE. A possible
gene regulatory role for an Ets-binding site has not been doc-
umented for the CYP24 gene, whereas a functional Jun/Fos
AP-1 site would be consistent with the observed action of TPA
(12-O-tetradecanoylphorbol-13-acetate) to up-regulate CYP24
enzyme activity (23). Consequently, these two sites were eval-
uated for possible roles in facilitating the proximal VDRE func-
tionality in mediating the action of 1,25-(OH)2D3 to induce
expression of the CYP24 gene.
EXPERIMENTAL PROCEDURES
Materials—1,25-(OH)2D3 was supplied by Hoffmann-La Roche. A
Sequenase version 2.0 sequencing kit was purchased from U. S. Bio-
chemical Corp. Oligonucleotides were synthesized by Bresatec (Ade-
laide, South Australia). The luciferase assay kit was from Promega
(Madison, WI). Nickel-nitrilotriacetic acid chromatographic support
and glutathione-agarose were from Qiagen GmbH (Germany).
Promoter-Luciferase Constructs and Expression Plasmids—Two oli-
gonucleotide polymerase chain reaction primers engineered with KpnI
sites were employed to amplify 2186 bp of the CYP24 promoter se-
quence (encompassing the proximal VDRE at 2150/2136) together
with 74 bp of 59-untranslated region using the pCYP24WT(2298)-Luc
plasmid (18) as a template. The polymerase chain reaction product was
cloned at the KpnI site in pGL3-Basic vector containing the firefly
luciferase reporter gene as described previously (24). Mutations in
promoter-luciferase constructs (see Fig. 1B) in VDRE half-sites, EBS,
and AP-1-like sites were introduced using the Quik-Change mutagen-
esis protocol (Stratagene, La Jolla, CA). The mutated constructs were
sequenced to verify the desired mutations. pRSV-hVDR was generated
by cloning human VDR cDNA sequence downstream of the Rous sar-
coma virus promoter (21). The expression clones for human Ets-1,
p42Ets-1, and Ets-2 are based on the pEFBOS vector and have been
described previously (25). Human Fli-1 and PU-1 expression clones
were kindly provided by Dr. Robert Hromas, Department of Medicine,
Indiana University. An activated Ras (Ha-c-Ras) expression clone
(pHO6T1), and expression clones for chicken p54-Ets-1 wild-type (c-
Ets-1 Thr-38) and mutated cEts-1 (c-Ets-1 T38A) were kindly provided
by Dr. Michael Ostrowski (Ohio State University) (26).
Maintenance and Transfection of Cells—Monkey kidney fibroblast
COS-1 cells were maintained in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal calf serum (FCS). In preparation for
electroporation, cells were grown in a 175-cm2 flask to 60–70% conflu-
ency, washed once with phosphate-buffered saline, and removed by
trypsinization. Transfections were performed by electroporation of cells
(2 3 106) in 500 ml of ice-cold electroporation buffer as described pre-
viously (24), containing 250 mg of sheared salmon sperm DNA and 2
pmol of promoter luciferase construct. The electroporation of COS-1
cells (280 V and 960 microfarads) was performed using a Bio-Rad gene
pulser. A reference plasmid, pRSV-bGal, was also included in the trans-
fections to correct for variations in transfection efficiency. Following
electroporation, the samples were placed on ice for 10 min and divided
into two wells of a 6-well plate containing Dulbecco’s modified Eagle’s
medium and 10% FCS. Cells were allowed to recover overnight, and
medium was replaced with RPMI and 10% charcoal-stripped FCS. Cells
were further treated with 1,25-(OH)2D3 (10
27 M) or ethanol carrier and
incubated for 24 h prior to harvesting. Luciferase activity in cell lysates
was determined as described previously (18). All cells used in transac-
tivation studies were cotransfected with the VDR-expression vector
pRSV-hVDR to compensate for a low endogenous VDR level in COS-1
cells (19).
Gel Mobility Shift Assays—Double-stranded oligonucleotides were
synthesized to contain the EBS and AP-1-like sites (CYP24-EBS), a
mutated core sequence of EBS (CYP24-mEBS), a mutated AP-1-like
sequence (CYP24-mAP1), the proximal VDRE alone (CYP24-VDRE), or
together with EBS as a composite oligonucleotide (VDRE 1 EBS). An
oligonucleotide that encompassed a known Ets-1-binding site from T-
cell receptor gene enhancer (TCRaEts-1) was employed as a control
(27). Each double-stranded oligonucleotide was designed with SalI and
XhoI restriction enzyme sites at the 59 or 39 ends as shown.
59-TCGACGCTGACTCCATCCTCTTC-39
39-GCGACTGAGGTAGGAGAAGAGCT-59
OLIGONUCLEOTIDE CYP24-EBS
59-TCGACGCTGACTCCAAAATCTTC-39
39-GCGACTGAGGTTTTAGAAGAGCT-59
OLIGONUCLEOTIDE CYP24-mEBS
59-TCGACGCGTTCTCCATCCTCTTC-39
39-GCGCAAGAGGTAGGAGAAGAGCT-59
OLIGONUCLEOTIDE CYP24-mAP1
59-TCGACGGCGCCCTCACTCACCTCGC-39
39-GCCGCGGGAGTGAGTGGAGCGAGCT-59
OLIGONUCLEOTIDE CYP24-VDRE
59-TCGACAGCCACATCCTCTGGAAC-39
39-GTCGGTGTAGGAGACCTTGAGCT-59
OLIGONUCLEOTIDE TCRaEts-1
59-TCGACGGCGCCCTCACTCACCTCGCTGACTCCATCCTCTTC-39
39-GCCGCGGGAGTGAGTGGAGCGACTGAGGTAGGAGAAGAGCT-59
OLIGONUCLEOTIDE VDRE 1 EBS
Nuclear extracts were prepared from COS-1 cells (28). Each double-
stranded oligonucleotide was labeled by end-filling with [a-32P]dCTP
using Klenow enzyme and purified by 12% polyacrylamide gel electro-
phoresis. Binding reactions for each assay contained 5 mg of nuclear
protein, 1 ml of poly(dI-dC) in a final volume of 12 ml in Dignum buffer
C (20 mM HEPES buffer, pH 7.6, 420 mM NaCl, 0.5 mM dithiothreitol, 5
mM MgCl2, 0.5 mM EDTA, 20% glycerol, and 0.5 mM phenylmethylsul-
fonyl fluoride) and were incubated on ice for 15 min. Radiolabeled probe
(200,000 cpm) was added, and samples were incubated on ice for an-
other 30 min. For gel-shift inhibition assays, a polyclonal antibody to
Ets protein DNA binding domain (PAN-Ets) was employed, and a VDR
monoclonal antibody designated IgG2b (Affinity BioReagents Inc., Ne-
shanic Station, NJ) was used as a control. For supershift assays, a
polyclonal antibody to Ets-1 (29) and a polyclonal antibody to Erg-1/
Erg-2 (Santa Cruz Biotechnology Inc.) were employed. These antibodies
were included in the binding reaction and incubated on ice for 15–30
min prior to addition of probe. Gel-shift competition assays were per-
formed with unlabeled competitor oligonucleotide at molar excess con-
centrations (50–100-fold) by inclusion in the binding reactions. Re-
tarded DNA nuclear protein complexes were resolved on a 4%
nondenaturing polyacrylamide gel using precooled low ionic strength
gel running buffer (0.53 TBE) at 4 °C. The gel was dried and exposed to
Kodak X-Omat AR film with an intensifying screen at 280 °C.
Gel Mobility Shift Assays Using Purified Ets-1, VDR, and RXR—
Recombinant full-length human Ets-1 (p54Ets-1) was produced in Esch-
erichia coli as a carboxyl histidine-tagged fusion protein and purified on
a nickel-nitrilotriacetic acid column. The tagged Ets-1 protein migrated
as a single band with an apparent molecular mass of about 55 kDa in
SDS-polyacrylamide gels. Recombinant VDR and RXR were produced
in E. coli as N-terminal glutathione S-transferase (GST) fusion pro-
teins. A clone pGEX-2T RXR, from Dr. George Muscat, University of
Queensland, Australia, expressed GST-RXR, and a clone (pGEX-2T
VDR) was created in our laboratory with human VDR cDNA cloned into
pGEX2T in frame with GST sequence. The GST-VDR and GST-RXR
fusion proteins were purified by affinity binding to glutathione-agarose
beads.
DNA binding reactions contained recombinant Ets-1, GST-VDR, or
GST-RXR with 50 ng of poly(dI-dC) in a final volume of 10 ml in binding
buffer (20 mM Tris-HCl buffer, pH 8.0, 100 mM NaCl, 5 mM dithiothre-
itol, 1.0 mM EDTA, pH 8.0, 10% glycerol, and 100 mg/ml bovine serum
albumin). Reactions were incubated at room temperature for 10 min.
Radiolabeled probes (10,000 cpm) were added and samples further
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incubated at room temperature for 20 min. For supershift assays and
competition binding assays, antibodies for Ets-1 and unlabeled compet-
itor oligonucleotides, respectively, were included prior to addition of
probe. Retarded complexes were resolved by 5% nondenaturing poly-
acrylamide gel electrophoresis. Association constants (Ka) for the bind-
ing of recombinant Ets-1 to CYP24-EBS and CYP24-mAP1 were deter-
mined by gel-shift assays. Increasing amounts of purified Ets-1 (0.125,
0.250, 0.500, and 1–4 mg) were incubated in a binding reaction with 1
ng of radiolabeled probe. The DNA protein complexes were resolved by
5% nondenaturing gel electrophoresis, dried, and exposed in the Phos-
phorImager (Molecular Dynamics). Ets-1-bound DNA complexes and
unbound-probe were quantified using ImageQuant Software. The asso-
ciation constants, defined as the Ets-1 concentration at which 50% of
the DNA probe was retarded, were determined by direct curve fitting
(Sigma Plot, Jandel Scientific).
RESULTS
Identification of a Functional Ets Protein-binding Site (EBS)
in the CYP24 Promoter—Previous expression studies (18) of the
rat CYP24 promoter suggested that 1,25-(OH)2D3-mediated
transactivation at the proximal VDRE (2136/2150) required
the participation of a nearby transcription factor(s). An exam-
ination of sequences downstream from this VDRE revealed a
likely binding site for Ets transcription factors (59-AGAGGAT-
GGA-39) at 2119/2128 on the antisense strand (Fig. 1A). Mem-
bers of the Ets transcription factor family bind to a common
core motif (59-GGA(A/T)-39) with flanking sequence determin-
ing the specificity of binding. The site identified here with a
59-GGAT-39 core, strongly resembles known binding sites for
Ets-1 (30). Also noted was a possible AP-1-like sequence (59-
TGACTCC-39) at 2132/2126, which differs from the consensus
AP-1 site (59-TGACTCA-39) by one nucleotide and overlaps the
Ets-binding site (EBS).
To evaluate whether the EBS contributes to 1,25-(OH)2D3-
dependent CYP24 promoter expression, the core EBS motif was
mutated (59-GGAT-39 to 59-TTTT-39) in a luciferase-reporter
construct that contained 2298 bp of promoter sequence and
both VDREs of the CYP24 promoter. The wild-type and mutat-
ed-EBS promoter constructs are designated pCYP24WT(2298)-
Luc and pCYP24mEBS(2298)-Luc, respectively (Fig. 1, B and
C). In response to 1,25-(OH)2D3, the wild-type construct gave a
27.2-fold level of induction, but this was reduced to 14.2-fold
when the EBS was inactivated (Fig. 2). The importance of the
EBS in sustaining the 1,25-(OH)2D3-mediated transactivation
of the CYP24 promoter constructs was explored further by
cotransfection studies with an Ets-1 expression vector. Cells
containing the pCYP24WT(2298)-Luc displayed more than a
doubling of activity (58.2-fold) when cotransfected with Ets-1
(Fig. 2). The mutant EBS construct in the presence of Ets-1
gave the same activity (14.5-fold) as observed for this mutated
construct in the absence of Ets-1 (Fig. 2). It was evident from
these studies, therefore, that the EBS was critical for maximal
up-regulation of the CYP24 promoter. Due to the location of the
EBS in the region downstream of the proximal VDRE, subse-
quent studies were conducted using constructs that contained
only the proximal promoter element and adjacent EBS and
AP-1-like sequences.
The single VDRE construct (2186 bp of promoter sequence;
pCYP24WT-Luc) expressed a 7.6-fold level of induction (Fig. 2),
which is about 28% of the value obtained with the construct
containing both functional VDREs (i.e. pCYP24WT(2298)-
Luc). This activity for the proximal VDRE is about 2-fold higher
than the contribution made by the more distal VDRE (data not
shown), which reflects the cooperative synergism between the
two VDREs in the rat CYP24 promoter (18). Mutation of the
EBS in the proximal VDRE construct (i.e. pCYP24mEBS-Luc)
resulted in a substantial loss in transactivation activity (7.6- to
4.2-fold) that was qualitatively similar to results obtained us-
ing the native two-VDRE construct (i.e. pCYPWT(2298)-Luc)
(Fig. 2). Transfected Ets-1 plasmid was ineffective in stimulat-
ing transactivation of the mutated EBS construct (i.e.
pCYP24mEBS-Luc, 4.3-fold induction), whereas induction was
increased from 7.6- to 14.0-fold in cells containing the wild-type
construct with an intact EBS (i.e. pCYP24WT-Luc) (Fig. 2). In
the absence of added 1,25-(OH)2D3, the basal level of expres-
sion of the wild-type construct was not affected by either EBS
inactivation or overexpression of Ets-1 (data not shown).
Mutagenesis of the VDRE alone (pCYP24mVDRE-Luc, Fig.
FIG. 1. Mutations introduced into the EBS and AP-1-like se-
quence and VDRE located in the rat CYP24 gene promoter. A,
sequence of native promoter encompassing the two VDREs, EBS and
AP-1-like sequence. The numbers above the lines indicate the distance
relative to the transcription initiation site. Arrows below the VDRE
sequence indicate VDRE hexameric half-sites and their orientation,
and arrows below EBS and the AP-1-like sequence indicate their ori-
entation. B, various mutations (shown in bold letters) that were intro-
duced in two different promoter length constructs (2186 and 2298). C,
diagrammatic representation of the wild-type CYP24 promoter-lucif-
erase construct of each promoter length (i.e. 174 to 2186 and 174 to
2298).
FIG. 2. The role of EBS and the influence of Ets-1 protein on
the 1,25-(OH)3D2-mediated transactivation of CYP24 promoter
constructs. COS-1 cells were cotransfected with pRSV-hVDR and
either pCYP24WT(2298)-Luc, pCYP24mEBS(2298)-Luc, pCYP24m-
EBS-Luc or pCYP24mVDRE-Luc. As an internal control, cells were
cotransfected with 5 mg of b-galactosidase expression vector, pRSV-bgal
(see “Experimental Procedures”). Each construct was tested for 1,25-
(OH)2D3-mediated (10
27 M) transactivation in the presence or absence
of a transfected Ets-1 construct (10 mg). The levels of induction (Fold
Vit-D Induction) are shown as the ratio of luciferase activity from
1,25-(OH)2D3-treated cells to that from untreated cells. Data presented
are the average of three independent experiments 6 S.D.
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1B) lowered induction of the wild-type construct to 1.2-fold
(Fig. 2) confirming that this is the only functional VDRE pres-
ent in the 2186 bp of promoter sequence as reported previously
(24). Overexpression of Ets-1 was also investigated on the
construct pCYP24mVDRE-Luc. In this situation, there was no
effect on expression in the presence of hormone (Fig. 2) con-
firming that Ets-1 cannot transactivate in the absence of a
functional VDRE. The data in Fig. 2 provide evidence for tran-
scriptional synergy between the EBS and VDRE. For example,
the 1,25-(OH)2D3 induction of the wild-type promoter construct
pCYP24WT-Luc in the presence of Ets-1 was 14.0-fold, which is
greater than the sum of the individual contributions from
VDRE (4.2-fold) and EBS (1.2-fold). When the constructs
pCYP24WT-Luc and pCYP24mEBS-Luc were tested at a lower
1,25-(OH)2D3 concentration (i.e. 10
210 M), a decrease in induc-
tion occurred for the wild-type construct (from 7.6 6 1.1- to
2.8 6 0.3-fold), and no induction was observed for the mEBS
construct. For comparison, the induction of the 2298 construct
(pCYP24WT(2298)-Luc) was also examined. At this low con-
centration of 1,25(OH)2D3, induction was lowered from 27.2 6
1.8- to 3.7 6 0.5-fold, and mutagenesis of the EBS led to the loss
of induction (1.5 6 0.25-fold). It is clear, therefore, that the EBS
is critical for the function of the proximal VDRE, especially
when hormone is near physiological concentration.
Specificity of Transactivation by Ets Proteins—The role of
EBS in stimulating CYP24 promoter activity was evaluated in
the transactivation assay using various Ets proteins. Ets fam-
ily members can be classified according to their homology to
Ets-1 (31). Class I members such as Ets-1 and Ets-2 have
extensive overall sequence similarity (30). Erg-1 and Fli-1,
class II members, show homology to Ets-1 both in their N-
terminal transactivation and C-terminal DNA binding do-
mains, whereas class III members such as PU.1 show homology
only in the DNA binding domain (30). We investigated the
ability of a representative member from each of the three
classes (human Ets-1, Fli-1, and PU.1) to transactivate the
wild-type CYP24 promoter in COS-1 cells. Neither Fli-1 nor
PU.1 further increased the 7.6-fold level of 1,25-(OH)2D3 induc-
tion observed with the pCYP24WT-Luc construct (Fig. 3). By
contrast, Ets-1 elevated 1,25-(OH)2D3 induction of the wild-
type construct to 14.0-fold (Fig. 3). The inability of Fli-1 or PU.1
to bind the EBS was not investigated.
The transactivation activity of p42Ets-1, an alternatively
spliced form of Ets-1 (32), and Ets-2, both class I members of
the Ets family, were also evaluated in overexpression studies.
The activity of p42Ets-1 was comparable to Ets-1, where it
stimulated the wild-type level of induction from 7.6- to 15.6-
fold, whereas Ets-2 was less active (7.6- to 10.8-fold) (Fig. 3). It
was further shown that the observed transactivation activities
of p42Ets-1 and Ets-2 were completely abrogated when the
EBS site in the promoter was mutated. Similar to Ets-1, nei-
ther p42Ets-1 nor Ets-2 altered basal expression of the wild-
type construct or expression of the mutant VDRE construct
(pCYP24mVDRE-Luc) in the presence or absence of hormone
(data not shown).
EBS Binds Multiple Proteins from COS-1 Cell Nuclear Ex-
tracts—To investigate nuclear protein binding to the EBS, gel
mobility shift analysis was carried out using COS-1 cell nuclear
extracts and the oligonucleotide probe CYP24-EBS. Six nucle-
ar-protein complexes (C1–C6) were consistently detected to-
gether with an inconsistently appearing band(s) between C3
and C4 (Fig. 4A). A similar profile of protein binding was
observed with a control Ets-1 probe (TCRaEts-1) from the
T-cell receptor a-gene enhancer (27), but the binding was
weaker than for CYP24-EBS (Fig. 4A). Mutagenesis of the core
region in CYP24-mEBS abolished the binding of all complexes
except C4 and C5 (data not shown). Self-competition experi-
ments inhibited formation of complexes C1–C3 and C6 (Fig.
4B). In contrast, competition experiments with the nonspecific
probe CYP24-VDRE and mutated probe CYP24-mEBS had no
effect on complexes C1–C3 and C6. However, the nonspecific
and mutated probes were partially active in preventing forma-
tion of the apparent nonspecific complexes migrating between
C3 and C6 (Fig. 4B). To characterize further the Ets proteins
FIG. 3. Activity of specific Ets proteins in the 1,25-(OH)2D3-
mediated transactivation of the CYP24 promoter. COS-1 cells
were cotransfected (see Fig. 2 and “Experimental Procedures”) with
pCYP24WT-Luc and one of five different Ets constructs (10 mg each)
and tested for 1,25-(OH)2D3-mediated transactivation of the CYP24
promoter construct. Data are the average of three independent exper-
iments 6 S.D.
FIG. 4. Binding of nuclear proteins to the EBS. A, double-
stranded oligonucleotides to EBS (CYP24-EBS) and a control EBS
(TCRaEts-1) were labeled by end-filling with [a-32P]dCTP and incu-
bated with nuclear extracts from COS-1 cells. The major retarded
complexes are arrowed and numbered as C1 to C6. Free probe is ar-
rowed at the bottom of the gel. B, the formation of complexes with
labeled CYP24-EBS in A was competed with three unlabeled probes (i.e.
self, nonspecific probe (CYP24-VDRE) or CYP24-mEBS). C, for neutral-
ization assays, nuclear extracts were incubated with (1) or without (2)
polyclonal antibodies for Ets (PAN-Ets, lane 2) or VDR monoclonal
antibody (VDRmab, lane 3) prior to addition of the labeled probe
CYP24-EBS.
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present in complexes C1–C6, gel mobility shift experiments
employing various antibodies were conducted. A neutralizing
polyclonal antibody (PAN-Ets) that interferes with the binding
of Ets proteins to the core sequence markedly reduced the
formation of complexes C1–C3 but only weakly affected C6 and
had no effect on C4 or C5 complex formation (Fig. 4C). Control
VDR monoclonal-neutralizing antibody was without effect (Fig.
4C). An Ets-1-supershifting polyclonal antibody (29) functioned
to supershift complexes C1, C2, and C3 (data not shown).
However, migration of complexes C1–C6 was not altered by
either a supershifting polyclonal antibody to the Ets proteins
Erg-1/Erg-2 or an Ets-2 polyclonal supershifting antibody (data
not shown). It can be concluded from the antibody gel mobility
shift data that EBS binds complexes C1–C3 and C6, which are
related immunologically to Ets-1. However, complexes C4 and
C5 appeared to be nonspecifically bound to the CYP24-EBS
probe. We have shown directly that purified Ets-1 binds to
CYP24-EBS but not to CYP24-mEBS (Fig. 5). The complex was
competed by self and TCRaEts-1 but not with a nonspecific
oligonucleotide or CYP24-mEBS. The recombinant Ets-1 com-
plex was found to comigrate with complex C3 (data not shown,
see Fig. 4 for binding complexes migration patterns).
An AP-1-like Sequence Overlaps the EBS—A possible AP-1-
like site (2132/2126) with a 3-base overlap at the 39-end of the
EBS on the antisense strand (Fig. 1A) was evaluated exten-
sively for functionality. Protein binding to this site was not
observed in gel mobility shift assays with either purified c-Fos
or c-Jun protein or with nuclear extracts from phorbol ester-
treated cells. Furthermore, overexpression of c-Fos and c-Jun
failed to alter CYP24 promoter expression (data not shown).
Therefore, rather than functioning as a classical AP-1 site, the
possibility was considered that the AP-1-like sequence repre-
sents extended EBS-flanking sequence. To investigate this hy-
pothesis, both the putative AP-1-like sequence and the EBS
were mutated (i.e. pCYP24mAP1-Luc and pCYP24mEBS-Luc)
and compared for transactivation activity. Induction with 1,25-
(OH)2D3 (7.6-fold) was lowered to 5.8-fold when the AP-1-like
site was mutated, whereas mutagenesis of the core EBS re-
duced induction to 4.2-fold (Fig. 6). A double mutation of both
sites gave a similar activity level to that seen with the core EBS
mutation (data not shown). Hence, mutagenesis of the AP-1-
like sequence does not further inhibit induction of the construct
with the inactivated EBS core motif. On this basis, it was
concluded that the 59-TGA-39 sequence constitutes flanking
sequence that is important for maximal EBS activity. Presum-
ably, the remaining sequence of the AP-1-like site also contrib-
utes to the EBS-flanking sequence (Fig. 1A).
To investigate further the AP-1-like sequence, transactiva-
tion experiments with Ets-1 were performed. When Ets-1 was
overexpressed, induction by 1,25-(OH)2D3 of the wild-type con-
struct was 14.0-fold, which was reduced to 8.2-fold with
pCYP24mAP1-Luc (Fig. 6). By comparison, mutagenesis of the
EBS core gave a 4.2-fold level of induction, and overexpressed
Ets-1 was ineffective (Fig. 6). Hence, alteration of the flanking
sequence substantially reduces transactivation by Ets-1. Con-
sistent with the transactivation studies, gel mobility shift as-
says with CYP24-mAP1 showed reduced binding of complexes
C1–C3 and C6 (data not shown). Association constants (Ka)
were determined in the gel mobility shift assays for the binding
of recombinant Ets-1 to CYP24-EBS and CYP24-mAP1 probes.
By using the wild-type probe, the Ka value for Ets-1 was 1.2 6
0.12 3 106 M21, which was decreased by ;25% to 0.89 6 0.09 3
106 M21 with probe containing the mutated flanking sequence.
This decrease in Ka for the CYP24-mAP1 probe supports fur-
ther the proposal that the 59-TGA-39 sequence from the AP-1-
like site is important for optimal binding of endogenous Ets
proteins. Based upon the collective data, it was evident that the
AP-1-like site was not functional. Therefore, subsequent stud-
ies were directed at delineating the detailed function of the
EBS to facilitate the transactivation activity of 1,25-(OH)2D3
on the rat CYP24 promoter.
Ets-1 and VDRzRXR Form a Ternary Complex on DNA—
Although the identity of the Ets proteins that bind to the EBS
in vivo are not known, we have demonstrated that this site can
respond to Ets-1 in transactivation experiments and bind re-
combinant Ets-1. On this basis, we investigated further the
mechanism of Ets-1 action. By using gel mobility shift analysis,
we showed that purified Ets-1, VDR, and RXR form a complex
on an oligonucleotide (VDRE 1 EBS) that spans both the
proximal VDRE and the EBS. When Ets-1 was incubated with
the probe, a single complex C-I was retarded (Fig. 7, lane 2),
and the amount of this complex was reduced by addition of
VDR and RXR with the appearance of a new slower mobility
complex C-II (lane 3). Complex C-II was also generated when
VDR and RXR were added to DNA prior to Ets-1 (data not
shown). The complex generated by VDR and RXR alone was
intermediate in size between complexes CI and CII (Fig. 7, lane
4). Formation of the complexes C-I, C-II, and VDR-RXR was
suppressed (lane 5) in the presence of excess unlabeled self-
competitor oligonucleotide (VDRE 1 EBS), which established
the specificity of these complex formations. To demonstrate
that C-II results from the formation of a ternary complex be-
tween Ets-1, VDR, RXR, and the VDRE 1 EBS probe, compe-
FIG. 5. Recombinant human p54Ets-1 binds to CYP24-EBS oli-
gonucleotide. Double-stranded oligonucleotides to EBS (CYP24-EBS),
mutated EBS (CYP24-mEBS), and a control EBS (TCRaEts-1) were
labeled by end-filling with [a-32P]dCTP and incubated with purified
Ets-1. A single complex was retarded on TCRaEts-1 (lane 1) and
CYP24-EBS (lane 2), but no complex was observed with CYP24-mEBS
(lane 7). The retarded complex on CYP24-EBS was competed with
100-fold molar excess of nonspecific (N.S.) competitor (lane 3), self-
competitor (lane 4), TCRaEts-1 (lane 5), and CYP24-mEBS (lane 6).
FIG. 6. CYP24-AP1-like sequence is the flanking sequence for
EBS. COS-1 cells were cotransfected with either pCYP24WT-Luc,
pCYP24mEBS-Luc, or pCYP24mAP1 (see Fig. 2 and “Experimental
Procedures”). CYP24 promoter constructs were tested for 1,25-(OH)2D3-
mediated transactivation in the presence or absence of transfected
Ets-1 expression clone (10 mg). Data presented are the average of three
independent experiments 6 S.D.
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tition experiments were performed. The competition by 100-
fold molar excess of an oligonucleotide corresponding to the
VDRE (CYP24-VDRE) resulted in conversion of complex C-II
into complex C-I (lane 6), whereas competition with an excess
of an oligonucleotide corresponding to the EBS site (CYP24-
EBS) resulted in conversion of complex II to the VDRzRXR
complex (lane 7). This confirmed that the slower migrating
complex II contains Ets-1 and the VDRzRXR complex and that
both binding sites (VDRE and EBS) are required for this ter-
nary complex formation. In these experiments, we consistently
observed a preferential binding of VDRzRXR to the preformed
Ets-1zVDRE 1 EBS complex (C-I) rather than to free VDRE 1
EBS probe (compare lane 3, where VDR-RXR was added to
preformed Ets-1zVDRE 1 EBS complex, and lane 4, where
VDR-RXR was added to free VDRE 1 EBS). A similar obser-
vation of preferential binding was made in titration experi-
ments using different concentrations of VDRzRXR and fixed
Ets-1 as well as in the reverse experiments (data not shown).
This finding raises the possibility of a physical interaction
between VDRzRXR and Ets-1, the details of which require
further investigation.
The EBS in the CYP24 Promoter Is a Ras/Raf-responsive
Element—The Ras/Raf signaling pathway plays a key role in
the activation of Ets-1 through phosphorylation of threonine
residue 38 (26, 33). We investigated whether a similar Ras-
mediated action is involved in the transactivation of the CYP24
promoter by exogenous Ets-1. Initial tests used wild-type
cEts-1 (the p54 form of chicken Ets-1) and a mutant form where
threonine 38 was mutated to an alanine (i.e. T38A) (26). Over-
expression of cEts-1 increased 1,25-(OH)2D3 induction of
pCYP24WT-Luc from 7.6- to 11.6-fold (Fig. 8). When the EBS
was mutated, there was no effect of overexpressed cEts-1 on
induction (data not shown). By contrast, overexpression of the
T38A mutant reduced the level of induction from 7.6- to 4.4-
fold, a level comparable to that observed when the EBS was
mutated (see Fig. 8). These results were interpreted to mean
that the mutant protein competes with endogenous Ets pro-
teins for binding to EBS but is unable to enhance transactiva-
tion. Therefore, these experiments establish threonine 38 as a
critical residue for cEts-1 transactivation and imply that the
Ras pathway is involved in cEts-1 function.
When Ras was overexpressed, the level of induction of the
pCYP24WT-Luc construct was increased from 7.6- to 11.2-fold,
and this was further increased to 16.4-fold when wild-type
cEts-1 was also transfected (Fig. 8). The Ras-dependent trans-
activation was completely inhibited when the EBS was mu-
tated (Fig. 8). When the T38A mutant cEts-1 was overex-
pressed, the Ras-mediated level of induction was lowered to
4.9-fold, which corresponded to the level of induction observed
with the mutated EBS (Fig. 8). When the VDRE was mutated
(i.e. pCYP24mVDRE-Luc), there was no effect of exogenous Ras
on either basal expression or 1,25-(OH)2D3-dependent induc-
tion (Fig. 8) in keeping with the conclusion that the VDRE is
critical for EBS function.
Further evidence for the involvement of endogenous Ras
activity was obtained with manumycin A, an inhibitor of Ras
farnesylation (35). The inhibitor was not effective at 10 mM, but
when tested at 50 mM, 1,25-(OH)2D3-dependent induction of
pCYP24WT-Luc was lowered from 7.7- to 4.1-fold, and the
same result was observed with inhibitor at 100 mM. This level of
expression was equivalent to that observed with mutated EBS
(e.g. see Fig. 2). Additionally, there was no effect of manumycin
A on induction when the EBS was inactivated. Hence, in these
cells, the Ras signaling pathway appears to be entirely respon-
sible for Ets protein activation.
Ets-1 Increases Basal Expression in Presence of a VDR Ho-
modimer—Ets-1 was unable to alter basal expression even in
the presence of overexpressed Ras. In a related manner, we
have recently shown that the binding of VDRzRXR inhibits
basal expression of the CYP24 promoter possibly through the
action of a corepressor (24). The binding or activation of Ets-1
could be prevented by the putative corepressor. As seen in Fig.
FIG. 7. Purified VDR, RXR, and Ets-1 form a ternary complex
with VDRE 1 EBS oligonucleotide. A double-stranded oligonucleo-
tide encompassing VDRE and the EBS site (VDRE 1 EBS) was labeled
by end-filling with [a-32P]dCTP and incubated either with purified
Ets-1 (lane 2) or VDR and RXR (lane 4), and the specific complexes are
indicated by arrows. In lanes 3, 5, 6, and 7, the probe was preincubated
with purified Ets-1 for 15 min followed by addition of VDR and RXR.
The specific complexes retarded (arrowed) were for Ets-1 alone (CI),
VDR-RXR complex, and a unique complex (CII) resulting from the
addition of VDR and RXR. CII was competed by 100-fold molar excess
of self-competitor (lane 5), CYP24-VDRE alone (lane 6), and CYP24-
EBS alone (lane 7). This experiment was repeated three times, and the
same result was obtained.
FIG. 8. Ras and cEts-1 Thr-38 stimulate 1,25-(OH)2D3 directed
induction of the CYP24 promoter. COS-1 cells were cotransfected
with either pCYP24WT-Luc, pCYP24mEBS-Luc, or pCYP24mVDRE-
Luc together with 10 mg of wild-type c-Ets-1 Thr-38 or mutated c-Ets-1
T38A expression clones (see Fig. 2). CYP24 promoter constructs were
tested for 1,25-(OH)2D3-mediated transactivation in the presence or
absence of transfected Ras expression clone (10 mg) (see “Experimental
Procedures”). Data presented are the average of three independent
experiments 6 S.D.
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9, however, basal expression was increased when cells were
transfected with a mutant form of VDR (VDRDE) that strongly
binds to the VDRE as a homodimer (24). Overexpression of
Ets-1 (together with the mutant VDR) consistently resulted in
a further increase in basal expression (Fig. 9). This result
indicates that the presence of unliganded VDRzRXR on the
promoter, but not VDRDE, prevents the action of Ets-1. Based
upon the current results and our previous work (24), we favor
a model in which the putative corepressor-complex bound to
unliganded VDRzRXR is responsible for EBS inactivity during
basal conditions.
DISCUSSION
Previous results from our laboratory (18) and others (19, 20)
have shown that the first 300 bp of rat CYP24 promoter se-
quence is required for the 1,25-(OH)2D3 regulation of gene
expression. The hormone-initiated transactivation is mediated
through two VDREs located at 2136/2150 and 2244/2258.
Interestingly, the proximal VDRE supports transactivation to a
greater extent than does the distal VDRE. The molecular basis
of this observation was investigated in the current study by
evaluating sites immediately adjacent to the proximal VDRE
that could function to alter VDR-RXR-initiated transactiva-
tion. We subsequently identified a possible AP-1 site (2132/
2126) and a consensus Ets-binding site (2128/2119) that were
juxtaposed to the proximal VDRE in both the rat and human
(34) CYP24 promoters. The molecular role of the two binding
sites in promoting the gene-regulatory action of 1,25(OH)2D3
was the current project focus.
The presence of a functional AP-1 site in the promoter of the
CYP24 gene has been suggested from various studies in which
24-hydroxylase enzyme activity was shown to be stimulated in
response to treatment with the phorbol ester TPA (23, 36, 37).
The role of TPA as a potent stimulator of protein kinase C
(PKC) activity is well documented, and many of its actions are
expressed through the Jun/Fos AP-1 system (38, 39). Also ap-
plicable to the current study is the observation that composite
AP-1/Ets sites can function in a cooperative fashion to regulate
gene expression (40). Consequently, the possibility was consid-
ered that the AP-1 sequence near the proximal VDRE could be
involved in the action of phorbol esters to stimulate expression
of the 24-hydroxylase enzyme. However, the AP-1-like se-
quence site was found to not be a functional AP-1 site, but it
was demonstrated instead to constitute a 39-flanking sequence
of the EBS on the antisense strand. Therefore, if an AP-1 site is
involved in mediating the up-regulation of CYP24 gene expres-
sion of TPA, it must be located in another region of the
promoter (41).
The identified Ets-binding site (EBS) was located approxi-
mately two turns of the helix downstream from the proximal
VDRE. It was found to contain a 59-GGAT-39 core sequence that
has been shown by other investigators (30) to provide specific-
ity for the binding of Ets-1 and other closely related Ets pro-
teins. In the corresponding position in the human CYP24 pro-
moter, the same EBS is present although it differs by one
nucleotide in the flanking region (33). The functionality of the
EBS in the rat CYP24 promoter was evaluated by transient
expression analysis of constructs that contained both VDREs or
only the proximal VDRE. In both instances, mutagenesis of the
core sequence within the EBS did not alter basal expression of
the construct but lowered the level of 1,25-(OH)2D3 induction.
Participation of an Ets protein in the induction mechanism was
strongly supported by the finding that overexpression of either
Ets-1, p42Ets-1, or Ets-2 markedly increased the transactiva-
tion response to 1,25-(OH)2D3 in which stimulation by the Ets
proteins was totally dependent upon an intact EBS. For exam-
ple, transactivation by Ets-1 resulted in a 14-fold induction of
the proximal VDRE construct, which was reduced by 70% when
the EBS was mutated. By comparison, promoter induction was
not affected by overexpression of the class II Fli-1 or class III
PU.1 proteins. It was concluded, therefore, that specific Ets
proteins, closely related to Ets-1 and representing class I mem-
bers (31), can stimulate 1,25-(OH)2D3-dependent induction in
transactivation experiments. The inactivity of Fli-1 and PU.1
could reflect their inability to bind the EBS in the CYP24
promoter. The stimulatory action of the alternatively spliced
isozyme p42Ets-1 is interesting, since this protein failed in
other studies to transactivate a functional EBS in the human
GM-CSF promoter.2 The distribution and relevance of this
isozyme to CYP24 gene regulation in kidney and other tissues
remains unknown.
The EBS in the CYP24 promoter bound six protein com-
plexes in the COS-1 cell nuclear extracts as determined by gel
mobility shift analysis. Formation of four of the complexes
(C1–C3, C6) was inhibited in self-competition experiments. The
three larger complexes (i.e. C1–C3) were supershifted with
Ets-1-specific polyclonal antibody and neutralized with a PAN-
Ets antibody. Based upon gel mobility shift studies with pure
protein, complex C3 appeared to be an Ets-1 complex. However,
the identity of this complex and the other two higher molecular
weight complexes remains to be conclusively determined. The
fourth and smallest Ets complex (i.e. C6) displayed lower spec-
ificity as it did not supershift, and neutralization of its binding
to EBS with the PAN-Ets competitive antibody was weak.
Recently, another Ets protein with similarities to Ets-1 was
identified in kidney and other tissues (42). Such observations
emphasize the challenge in identifying a specific endogenous
Ets protein(s) that stimulates CYP24 promoter induction. A
similar problem has arisen in other studies where in vitro
binding of multiple Ets proteins to a single functional EBS has
been observed (25, 43).
Mutagenesis of the EBS and VDRE motifs in transactivation
experiments provided evidence for transcriptional synergism
between the two sites in response to hormone. This cooperation
may reflect a direct interaction between the Ets-1 type protein
and liganded VDRzRXR complex on the CYP24 promoter. Al-
though this remains to be demonstrated, numerous other stud-
ies have established synergy between Ets-1 and transcription
factors on both cellular and viral promoters (44–52), between
2 P. P. Dwivedi, J. L. Omdahl, I. Kola, D. A. Hume, and B. K. May,
unpublished data.
FIG. 9. Ets-1 increases basal expression of CYP24 promoter
expression in the presence of VDRDE. COS-1 cells were cotrans-
fected with either pCYP24WT-Luc and pSG5-VDRDE (1 mg)(24) or
p54-Ets-1 (10 mg) (see Fig. 2 and “Experimental Procedures”), but they
were not treated with 1,25-(OH)2D3 due to the measurement of basal
activity. Luciferase activity of pCYP24WT-Luc is taken as 100%, and
activities are expressed relative to this value. Data presented are the
average of three independent experiments 6 S.D.
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Ets-1 and a partner protein (43–45, 47, 49), or an indirect
interaction of Ets via the coactivator CBP (53). Ets-1 possesses
internal negative regulatory domains that hinder its mono-
meric binding to DNA (54), and therefore, the interaction with
a neighboring protein would facilitate binding to the promoter
(55, 56). The lack of such an interaction would explain why the
EBS is inactive when the proximal VDRE is mutated in the
CYP24 promoter.
Ets proteins have been identified as key nuclear mediators of
Ras/Raf action. There is recent evidence that the ability of
Ets-1 to transactivate promoters is dependent upon its phos-
phorylation at a conserved threonine (residue 38) by the Ras/
Raf pathway (26). However, phosphorylation of Ets-1 is appar-
ently not required on some Ets-1-responsive promoters (26).
Endogenous Ras was demonstrated in the current study to be
important for Ets protein activation. Ras overexpression sub-
stantially enhanced the 1,25-(OH)2D3 induction of the CYP24
promoter, and the Ras response was totally dependent on an
intact EBS. Furthermore, Ras overexpression potentiated
transactivation by Ets-1, but Ras was ineffective with the T38A
mutant Ets-1 protein in which threonine 38 was not available
for phosphorylation. Interestingly, expression of the T38A mu-
tant protein reduced the level of 1,25-(OH)2D3-induced expres-
sion to the activity observed by a CYP24 promoter construct in
which the EBS was mutated. It is apparent from studies with
the CYP24 proximal promoter that mutant T38A Ets protein
can bind to the EBS and not be transcriptionally active. There-
fore, Ets-enhanced transactivation at the proximal CYP24 pro-
moter region appears to occur through its phosphorylated thre-
onine, which may be necessary for the interaction of the
coregulator with VDRzRXR or the transcription machinery. In
a recent report (57), Ras transformation of human keratino-
cytes resulted in the inactivation of VDRzRXR complex forma-
tion, but the relationship of this finding to the Ras-mediated
activation of 1,25(OH)2D3 induction in the present work re-
mains to be established.
An intriguing observation in the current study involved the
lack of response for the EBS in the absence of 1,25-(OH)2D3
ligand. There is evidence for the binding of a repressor complex
to unliganded VDRzRXR (24), and this could prevent either Ets
protein binding or its facilitation of a transactivation response.
The current experiments in which a VDR mutant (VDRDE)
allowed Ets-1 to increase basal expression demonstrated fur-
ther the repressive nature of the unliganded VDRzRXR complex
and the requirement of a partner protein for Ets-1
functionality.
The contribution of the EBS site to 1,25-(OH)2D3 induction
was particularly noticeable when the concentration of 1,25-
(OH)2D3 was lowered from the non-limiting concentration used
routinely in this work (1027 M) to a more physiological concen-
tration of 10210 M. At this concentration of 1,25-(OH)2D3, ac-
tivity of the proximal VDRE was almost entirely dependent on
a functional EBS. This result demonstrates the important role
played by the EBS at or near physiological concentrations of
1,25-(OH)2D3. Under such conditions, the activity of limiting
amounts of bound liganded VDRzRXR to the proximal VDRE
may be critically dependent on a cooperative interaction with
the nearby Ets protein. Regulation of CYP24 gene expression
by 1,25-(OH)2D3 constitutes a feedback control mechanism
whereby 1,25-(OH)2D3 regulates its own ambient concentra-
tion. Induced levels of CYP24 would result in the increased
oxidation of 1,25-(OH)2D3 to water-soluble products and sub-
sequent excretion (16). A synergistic response between the
VDREs at higher levels of hormone would ensure maximal
promoter activity and the rapid removal of excess 1,25-
(OH)2D3. At lower hormone levels, in contrast, promoter ex-
pression would expectantly be weaker and result in lowered
CYP24-mediated degradation of 1,25(OH)2D3 due to the domi-
nant action of the proximal VDRE in which the EBS-binding
proteins play a key role.
The present work represents the first report where Ets pro-
teins have been shown to contribute to 1,25-(OH)2D3-depend-
ent promoter activity. Since several Ets proteins are coex-
pressed in most tissues (42, 58), it remains a challenge to
determine which of these is required for activity on the CYP24
promoter. We demonstrated in COS-1 cells that signaling by
Ras is essential for Ets-1 activation. However, PKC activity
may also be important for CYP24 promoter expression (23, 36,
37). There are reports that 1,25-(OH)2D3 stimulates PKC ac-
tivity (59, 60), and recently, a plasma membrane VDR was
identified that mediated PKC activation in response to 1,25-
(OH)2D3 (61, 62). This finding gives rise to the interesting
possibility that CYP24 promoter expression in response to 1,25-
(OH)2D3 may be controlled at one or both extranuclear sites,
involving PKC and Ras/Raf signaling. In that regard, it is
evident from this study that the combined action of 1,25-
(OH)2D3 and mitogen-activated protein kinase pathway activ-
ity can facilitate a rapid response of the CYP24 gene to 1)
tightly regulate ambient 1,25-(OH)2D3 levels and, thereby, pre-
vent elevations in the hormone and calcium that would be toxic
to critical organ functions, and 2) modulate synthesis of 24-
hydroxylated metabolites that express important biological
functions. Whether 1,25-(OH)2D3 can directly activate Ras in
the CYP24 promoter system remains an interesting issue for
future studies.
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